APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Rabies Immunoglobulin (IM)

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)

Selected research

Market Outlook & Growth Opportunities

Global Human Rabies Immunoglobulin (IM) Market Outlook and Growth Opportunities 2026

26 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Rabies Immunoglobulin (IM) Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Rabies Immunoglobulin (IM) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Human Rabies Immunoglobulin (IM) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Rabies Immunoglobulin (IM) Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Rabies Immunoglobulin (IM) Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Rabies immunoglobulin (RIG) is a medication made up of antibodies against the rabies virus. It is used to prevent rabies following exposure.

Figure Human Rabies Immunoglobulin (IM) is rabies immunoglobulin antibody by the high price of healthy human plasma protein low temperature ethanol separation or other separation methods approved separation and purification, and by virus removal and inactivation treatment is made. Mainly used for rabies or other crazy animal bites, scratches patient's passive immunization.

In this report, we study ERIG (Equine Rabies Immunoglobulin) and HRIG (Human Rabies Immunoglobulin)

Read the full market overview

Global Human Rabies Immunoglobulin (IM) key players include CSL Behring, Grifols, Sanofi, etc. Global top three manufacturers hold a share about 60%.

North America is the largest market, with a share over 30%, followed by China and Europe, both have a share about 45 percent.

In terms of product, HRIG is the largest segment, with a share over 85%. And in terms of application, the largest application is Category III Exposure, followed by Category II Exposure.

This report provides an overview of the global Human Rabies Immunoglobulin (IM) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Rabies Immunoglobulin (IM) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Rabies Immunoglobulin (IM) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Rabies Immunoglobulin (IM) market size, projected growth trends, production technologies, key applications, and end-use industries.

Human Rabies Immunoglobulin (IM) Segment by Company

CSL Behring

Grifols

Sanofi

Sichuan Yuanda Shuyang

CNBG

Kamada

CBPO

Shuanglin Bio

Weiguang Bio

Shanghai RAAS

Bharat Serum

VINS

Human Rabies Immunoglobulin (IM) Segment by Type

ERIG

HRIG

Human Rabies Immunoglobulin (IM) Segment by Application

Category II Exposure

Category III Exposure

Human Rabies Immunoglobulin (IM) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Human Rabies Immunoglobulin (IM) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Human Rabies Immunoglobulin (IM) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Rabies Immunoglobulin (IM) significant trends, drivers, influence factors in global and regions.

6. To analyze Human Rabies Immunoglobulin (IM) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Rabies Immunoglobulin (IM) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Rabies Immunoglobulin (IM) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Rabies Immunoglobulin (IM).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Human Rabies Immunoglobulin (IM) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Rabies Immunoglobulin (IM) industry.

Chapter 3: Detailed analysis of Human Rabies Immunoglobulin (IM) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Human Rabies Immunoglobulin (IM) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Human Rabies Immunoglobulin (IM) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Rabies Immunoglobulin (IM) Industry Trends Table 2. Human Rabies Immunoglobulin (IM) Industry Drivers Table 3. Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges Table 4. Human Rabies Immunoglobulin (IM) Industry Restraints Table 5. Global Human Rabies Immunoglobulin (IM) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Rabies Immunoglobulin (IM) Revenue Share by Company (2021-2026) Table 7. Global Human Rabies Immunoglobulin (IM) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Company (2021-2026) Table 9. Global Human Rabies Immunoglobulin (IM) Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Human Rabies Immunoglobulin (IM) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Human Rabies Immunoglobulin (IM) Key Company Manufacturing Base & Headquarters Table 12. Global Human Rabies Immunoglobulin (IM) Company, Product Type & Application Table 13. Global Human Rabies Immunoglobulin (IM) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Human Rabies Immunoglobulin (IM) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ERIG Table 18. Significant Companies of HRIG Table 19. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Type (2021-2026) Table 23. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Type (2027-2032) Table 24. Global Human Rabies Immunoglobulin (IM) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Type (2021-2026) Table 28. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Category II Exposure Table 30. Significant Companies of Category III Exposure Table 31. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Application (2021-2026) Table 35. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Application (2027-2032) Table 36. Global Human Rabies Immunoglobulin (IM) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Application (2021-2026) Table 40. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Application (2027-2032) Table 41. Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Human Rabies Immunoglobulin (IM) Sales by Region (2021-2026) & (K Units) Table 43. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2021-2026) Table 44. Global Human Rabies Immunoglobulin (IM) Sales by Region (2027-2032) & (K Units) Table 45. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region (2027-2032) Table 46. Global Human Rabies Immunoglobulin (IM) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Region (2021-2026) Table 49. Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Region (2027-2032) Table 51. Global Human Rabies Immunoglobulin (IM) Market Average Price (USD/Unit) by Region (2021-2026) Table 52. Global Human Rabies Immunoglobulin (IM) Market Average Price (USD/Unit) by Region (2027-2032) Table 53. Global Human Rabies Immunoglobulin (IM) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Human Rabies Immunoglobulin (IM) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026) & (K Units) Table 56. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2021-2026) Table 57. Global Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032) & (K Units) Table 58. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Country (2027-2032) Table 59. Global Human Rabies Immunoglobulin (IM) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Human Rabies Immunoglobulin (IM) Sales Value Market Share by Country (2021-2026) Table 61. Global Human Rabies Immunoglobulin (IM) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Human Rabies Immunoglobulin (IM) Sales Value Market Share by Country (2027-2032) Table 63. CSL Behring Company Information Table 64. CSL Behring Business Overview Table 65. CSL Behring Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 66. CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio Table 67. CSL Behring Recent Development Table 68. Grifols Company Information Table 69. Grifols Business Overview Table 70. Grifols Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 71. Grifols Human Rabies Immunoglobulin (IM) Product Portfolio Table 72. Grifols Recent Development Table 73. Sanofi Company Information Table 74. Sanofi Business Overview Table 75. Sanofi Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 76. Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio Table 77. Sanofi Recent Development Table 78. Sichuan Yuanda Shuyang Company Information Table 79. Sichuan Yuanda Shuyang Business Overview Table 80. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 81. Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio Table 82. Sichuan Yuanda Shuyang Recent Development Table 83. CNBG Company Information Table 84. CNBG Business Overview Table 85. CNBG Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 86. CNBG Human Rabies Immunoglobulin (IM) Product Portfolio Table 87. CNBG Recent Development Table 88. Kamada Company Information Table 89. Kamada Business Overview Table 90. Kamada Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Kamada Human Rabies Immunoglobulin (IM) Product Portfolio Table 92. Kamada Recent Development Table 93. CBPO Company Information Table 94. CBPO Business Overview Table 95. CBPO Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. CBPO Human Rabies Immunoglobulin (IM) Product Portfolio Table 97. CBPO Recent Development Table 98. Shuanglin Bio Company Information Table 99. Shuanglin Bio Business Overview Table 100. Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio Table 102. Shuanglin Bio Recent Development Table 103. Weiguang Bio Company Information Table 104. Weiguang Bio Business Overview Table 105. Weiguang Bio Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio Table 107. Weiguang Bio Recent Development Table 108. Shanghai RAAS Company Information Table 109. Shanghai RAAS Business Overview Table 110. Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio Table 112. Shanghai RAAS Recent Development Table 113. Bharat Serum Company Information Table 114. Bharat Serum Business Overview Table 115. Bharat Serum Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio Table 117. Bharat Serum Recent Development Table 118. VINS Company Information Table 119. VINS Business Overview Table 120. VINS Human Rabies Immunoglobulin (IM) Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. VINS Human Rabies Immunoglobulin (IM) Product Portfolio Table 122. VINS Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Human Rabies Immunoglobulin (IM) Distributors List Table 126. Human Rabies Immunoglobulin (IM) Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Human Rabies Immunoglobulin (IM) Product Image Figure 2. Global Human Rabies Immunoglobulin (IM) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Human Rabies Immunoglobulin (IM) Sales (2021-2032) & (K Units) Figure 5. Global Human Rabies Immunoglobulin (IM) Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Human Rabies Immunoglobulin (IM) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ERIG Image Figure 10. HRIG Image Figure 11. Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Human Rabies Immunoglobulin (IM) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Type (2021-2032) Figure 14. Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Rabies Immunoglobulin (IM) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Type (2021-2032) Figure 17. Category II Exposure Image Figure 18. Category III Exposure Image Figure 19. Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Human Rabies Immunoglobulin (IM) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Application (2021-2032) Figure 22. Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Human Rabies Immunoglobulin (IM) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Application (2021-2032) Figure 25. Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Human Rabies Immunoglobulin (IM) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Human Rabies Immunoglobulin (IM) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Human Rabies Immunoglobulin (IM) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Human Rabies Immunoglobulin (IM) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Human Rabies Immunoglobulin (IM) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Human Rabies Immunoglobulin (IM) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Human Rabies Immunoglobulin (IM) Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Human Rabies Immunoglobulin (IM) Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • ERIG
  • HRIG
Applications
  • Category II Exposure
  • Category III Exposure
Companies covered
  • CSL Behring
  • Grifols
  • Sanofi
  • Sichuan Yuanda Shuyang
  • CNBG
  • Kamada
  • CBPO
  • Shuanglin Bio
  • Weiguang Bio
  • Shanghai RAAS
  • Bharat Serum
  • VINS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  4. 1.2.2 Global Human Rabies Immunoglobulin (IM) Sales Volume (2021-2032)
  5. 1.2.3 Global Human Rabies Immunoglobulin (IM) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Human Rabies Immunoglobulin (IM) Market Dynamics
  1. 2.1 Human Rabies Immunoglobulin (IM) Industry Trends
  2. 2.2 Human Rabies Immunoglobulin (IM) Industry Drivers
  3. 2.3 Human Rabies Immunoglobulin (IM) Industry Opportunities and Challenges
  4. 2.4 Human Rabies Immunoglobulin (IM) Industry Restraints
3 Human Rabies Immunoglobulin (IM) Market by Company
  1. 3.1 Global Human Rabies Immunoglobulin (IM) Company Revenue Ranking in 2025
  2. 3.2 Global Human Rabies Immunoglobulin (IM) Revenue by Company (2021-2026)
  3. 3.3 Global Human Rabies Immunoglobulin (IM) Sales Volume by Company (2021-2026)
  4. 3.4 Global Human Rabies Immunoglobulin (IM) Average Price by Company (2021-2026)
  5. 3.5 Global Human Rabies Immunoglobulin (IM) Company Ranking (2024-2026)
  6. 3.6 Global Human Rabies Immunoglobulin (IM) Company Manufacturing Base and Headquarters
  7. 3.7 Global Human Rabies Immunoglobulin (IM) Company Product Type and Application
  8. 3.8 Global Human Rabies Immunoglobulin (IM) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Human Rabies Immunoglobulin (IM) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Human Rabies Immunoglobulin (IM) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Human Rabies Immunoglobulin (IM) Market by Type
  1. 4.1 Human Rabies Immunoglobulin (IM) Type Introduction
  2. 4.1.1 ERIG
  3. 4.1.2 HRIG
  4. 4.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Type
  5. 4.2.1 Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Human Rabies Immunoglobulin (IM) Sales Value by Type
  9. 4.3.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Human Rabies Immunoglobulin (IM) Sales Value Share by Type (2021-2032)
5 Human Rabies Immunoglobulin (IM) Market by Application
  1. 5.1 Human Rabies Immunoglobulin (IM) Application Introduction
  2. 5.1.1 Category II Exposure
  3. 5.1.2 Category III Exposure
  4. 5.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Application
  5. 5.2.1 Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Human Rabies Immunoglobulin (IM) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Human Rabies Immunoglobulin (IM) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Human Rabies Immunoglobulin (IM) Sales Value by Application
  9. 5.3.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Human Rabies Immunoglobulin (IM) Sales Value Share by Application (2021-2032)
6 Human Rabies Immunoglobulin (IM) Regional Sales and Value Analysis
  1. 6.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Rabies Immunoglobulin (IM) Sales by Region (2021-2032)
  3. 6.2.1 Global Human Rabies Immunoglobulin (IM) Sales by Region: 2021-2026
  4. 6.2.2 Global Human Rabies Immunoglobulin (IM) Sales by Region (2027-2032)
  5. 6.3 Global Human Rabies Immunoglobulin (IM) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Region (2027-2032)
  9. 6.5 Global Human Rabies Immunoglobulin (IM) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  12. 6.6.2 North America Human Rabies Immunoglobulin (IM) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  15. 6.7.2 Europe Human Rabies Immunoglobulin (IM) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Human Rabies Immunoglobulin (IM) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  21. 6.9.2 South America Human Rabies Immunoglobulin (IM) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Human Rabies Immunoglobulin (IM) Sales Value Share by Country, 2025 VS 2032
7 Human Rabies Immunoglobulin (IM) Country-level Sales and Value Analysis
  1. 7.1 Global Human Rabies Immunoglobulin (IM) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Human Rabies Immunoglobulin (IM) Sales by Country (2021-2032)
  4. 7.3.1 Global Human Rabies Immunoglobulin (IM) Sales by Country (2021-2026)
  5. 7.3.2 Global Human Rabies Immunoglobulin (IM) Sales by Country (2027-2032)
  6. 7.4 Global Human Rabies Immunoglobulin (IM) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Human Rabies Immunoglobulin (IM) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Human Rabies Immunoglobulin (IM) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Human Rabies Immunoglobulin (IM) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Human Rabies Immunoglobulin (IM) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Human Rabies Immunoglobulin (IM) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Behring
  2. 8.1.1 CSL Behring Company Information
  3. 8.1.2 CSL Behring Business Overview
  4. 8.1.3 CSL Behring Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Behring Human Rabies Immunoglobulin (IM) Product Portfolio
  6. 8.1.5 CSL Behring Recent Developments
  7. 8.2 Grifols
  8. 8.2.1 Grifols Company Information
  9. 8.2.2 Grifols Business Overview
  10. 8.2.3 Grifols Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Grifols Human Rabies Immunoglobulin (IM) Product Portfolio
  12. 8.2.5 Grifols Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Human Rabies Immunoglobulin (IM) Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Sichuan Yuanda Shuyang
  20. 8.4.1 Sichuan Yuanda Shuyang Company Information
  21. 8.4.2 Sichuan Yuanda Shuyang Business Overview
  22. 8.4.3 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sichuan Yuanda Shuyang Human Rabies Immunoglobulin (IM) Product Portfolio
  24. 8.4.5 Sichuan Yuanda Shuyang Recent Developments
  25. 8.5 CNBG
  26. 8.5.1 CNBG Company Information
  27. 8.5.2 CNBG Business Overview
  28. 8.5.3 CNBG Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CNBG Human Rabies Immunoglobulin (IM) Product Portfolio
  30. 8.5.5 CNBG Recent Developments
  31. 8.6 Kamada
  32. 8.6.1 Kamada Company Information
  33. 8.6.2 Kamada Business Overview
  34. 8.6.3 Kamada Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kamada Human Rabies Immunoglobulin (IM) Product Portfolio
  36. 8.6.5 Kamada Recent Developments
  37. 8.7 CBPO
  38. 8.7.1 CBPO Company Information
  39. 8.7.2 CBPO Business Overview
  40. 8.7.3 CBPO Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 CBPO Human Rabies Immunoglobulin (IM) Product Portfolio
  42. 8.7.5 CBPO Recent Developments
  43. 8.8 Shuanglin Bio
  44. 8.8.1 Shuanglin Bio Company Information
  45. 8.8.2 Shuanglin Bio Business Overview
  46. 8.8.3 Shuanglin Bio Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Shuanglin Bio Human Rabies Immunoglobulin (IM) Product Portfolio
  48. 8.8.5 Shuanglin Bio Recent Developments
  49. 8.9 Weiguang Bio
  50. 8.9.1 Weiguang Bio Company Information
  51. 8.9.2 Weiguang Bio Business Overview
  52. 8.9.3 Weiguang Bio Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Weiguang Bio Human Rabies Immunoglobulin (IM) Product Portfolio
  54. 8.9.5 Weiguang Bio Recent Developments
  55. 8.10 Shanghai RAAS
  56. 8.10.1 Shanghai RAAS Company Information
  57. 8.10.2 Shanghai RAAS Business Overview
  58. 8.10.3 Shanghai RAAS Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai RAAS Human Rabies Immunoglobulin (IM) Product Portfolio
  60. 8.10.5 Shanghai RAAS Recent Developments
  61. 8.11 Bharat Serum
  62. 8.11.1 Bharat Serum Company Information
  63. 8.11.2 Bharat Serum Business Overview
  64. 8.11.3 Bharat Serum Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bharat Serum Human Rabies Immunoglobulin (IM) Product Portfolio
  66. 8.11.5 Bharat Serum Recent Developments
  67. 8.12 VINS
  68. 8.12.1 VINS Company Information
  69. 8.12.2 VINS Business Overview
  70. 8.12.3 VINS Human Rabies Immunoglobulin (IM) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 VINS Human Rabies Immunoglobulin (IM) Product Portfolio
  72. 8.12.5 VINS Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Human Rabies Immunoglobulin (IM) Value Chain Analysis
  2. 9.1.1 Human Rabies Immunoglobulin (IM) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Human Rabies Immunoglobulin (IM) Sales Mode & Process
  6. 9.2 Human Rabies Immunoglobulin (IM) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Human Rabies Immunoglobulin (IM) Distributors
  9. 9.2.3 Human Rabies Immunoglobulin (IM) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst